Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jan;14(1):33-40.

Hepatitis B Virus Infection and Organ Transplantation

Walid S Ayoub  1 , Paul Martin  1 , Kalyan Ram Bhamidimarri  1
Affiliations

Hepatitis B Virus Infection and Organ Transplantation

Walid S Ayoub et al. Gastroenterol Hepatol (N Y). 2018 Jan.

Abstract

Hepatitis B virus (HBV) infection remains an important cause of liver disease and continues to present several unique challenges in organ transplantation despite the availability of an effective vaccine to prevent HBV infection and the introduction of oral therapy to treat HBV infection over 20 years ago. HBV recurrence following liver transplantation can now be prevented with antiviral therapy, although controversy persists as to whether immunoprophylaxis with hepatitis B immunoglobulin is also necessary. HBV reactivation following organ transplantation can occur even in recipients with absent hepatitis B surface antigen at the time of transplantation and remains an important cause of morbidity and mortality. Expansion of the donor pool by using organs from hepatitis B core antibody-positive donors can result in HBV infection in the recipient. Another challenge is severe HBV reactivation leading to liver failure in HBV-infected patients receiving immunomodulatory agents, which are increasingly being used for a variety of nonneoplastic indications.

Keywords: Transplantation; hepatitis B core antibody; hepatitis B virus reactivation; hepatitis B virus recurrence.

PubMed Disclaimer

Conflict of interest statement

Dr Bhamidimarri has been a member of the Scientific Advisory Board for Gilead. The other authors have no relevant conflicts of interest to disclose.

Figures

Figure.
Figure.
A summary of prophylaxis recommendations for recipients of anti-HBc–positive liver grafts. Lamivudine is the most cost-effective nucleos(t)ide analogue, but any can be used for prophylaxis in naive patients.
See this image and copyright information in PMC

References

    1. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538. - PubMed
    1. Ghany MG, Perrillo R, Li R, et al. Hepatitis B Research Network. Characteristics of adults in the Hepatitis B Research Network in North America reflect their country of origin and hepatitis B virus genotype. Clin Gastroenterol Hepatol. 2015;13(1):183–192. - PMC - PubMed
    1. Maiwall R, Kumar M. Prevention and treatment of recurrent hepatitis B after liver transplantation. J Clin Transl Hepatol. 2016;4(1):54–65. - PMC - PubMed
    1. Lerut JP, Donataccio M, Ciccarelli O, et al. Liver transplantation and HBsAg-positive postnecrotic cirrhosis: adequate immunoprophylaxis and delta virus co-infection as the significant determinants of long-term prognosis. J Hepatol. 1999;30(4):706–714. - PubMed
    1. Urabe A, Imamura M, Tsuge M, et al. The relationship between HBcrAg and HBV reinfection in HBV related post–liver transplantation patients. J Gastroenterol. 2017;52(3):366–375. - PubMed

LinkOut - more resources